The independent panel, which reviewed a 23-page FDA briefing document highlighting recent studies, said more data is needed before it can recommend a third jab to people aged 16 years and older.

It found the two-dose Pfizer regimen is still highly protective against the spread of the highly contagious Delta variant — and denied recommending a booster because they aren’t needed at this time.

“In particular, there is a lack of data on effectiveness and duration,” Dr. Michael Carome, director of Public Citizen’s Health Research Group, said Friday.

“Current evidence does not appear to show a need for boosting.”